Navigation Links
InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
Date:10/3/2009

Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of their diagnostic ad preclinical grade material very fast and in highest quality, including authentic human glycosylation patterns, using the novel and proprietary CAP-TTM transient expression system.

CAP-TTM Technology is based on CAP cells, the stable cell line from CEVEC. The non-tumor origin cells have high expression rates of human proteins and grow in serum-free suspension culture and post-translational modifications are human-like. Process times are reduced by means of large-scale transient transfection.

After launching our new transient cell in the US market we are delighted to have now our first customers in Europe not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, e.g. HEK 293 freestyle and others, while offering highest quality human like proteins, we offer our customers a unique state of the art cell line, Wolfgang Kintzel, CCO of CEVEC Pharmaceuticals GmbH states.

Rainer Lichtenberger, CEO of CEVEC, adds. Because posttranslational modifications play a significant role for the bioactivity of recombinant proteins it is of crucial importance to produce proteins with human-like glycosylation and sialylation. With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only CEVEC is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This license agreement contributes significantly to CEVECs goal becoming the leading cell line supplier for protein production with human cell expression systems.


About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne, Germany. Based on their experience and theirlongstanding collaborative work they had experienced a lack of innovative expression systems formore efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVECs novel proprietary human CAP and CAP-T expression systems are ideal for manufacturing complex biopharmaceutical molecules with human glycosylation patterns.


About InVivo BioTech Services GmbH - www.invivo.de
InVivo is a contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. Based in Hennigsdorf, Germany, just outside Berlin, InVivo is an ISO 9001 certified company with over ten years experience in mammalian cell culture and protein production. More than 1100 different hybridomas have been cultivated in InVivos proprietary serum-free media ISF1 for high productivity and cost benefits in cultivation and purification. Furthermore InVivo offers the complete range of modern protein expression techniques. Starting from synthetic or amplified cDNA your protein can be stable expressed in bacteria, insect and mammalian cell lines or alternatively transient expressed.



Contact:
Wolfgang Kintzel
Chief Commercial Officer / Geschftsfhrer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Strae 62
D-51105 Kln
Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
kintzel@cevec-pharmaceuticals.com
www.cevec-pharmaceuticals.com


'/>"/>
b3c newswire

Related biology news :

1. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
2. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
3. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
4. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
5. Bacteria from sponges make new pharmaceuticals
6. MSU licenses plant oil enhancement technology to BASF Plant Science
7. UGA licenses technology to make fuel from dead forests and agricultural waste
8. UGA licenses new Bermuda grass that thrives in sun and shade
9. WARF signs license agreement with Pfizer for human embryonic stem cells
10. FluChip technology licensed to combat deadly flu virus
11. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
Breaking Biology Technology: